A groundbreaking study in Nature Cardiovascular Research uncovers promising drug targets for heart failure (HF) and its ...

Bayer seeks Japanese marketing approval for finerenone to treat adult patients with chronic heart failure: Berlin Saturday, February 15, 2025, 14:00 Hrs [IST] Bayer announced the ...

由于其高患病率和发病率，心力衰竭（HF）仍然是对患者和医疗专业人员构成重大威胁的疾病。以下是 European Heart Journal（EHJ）整理的 2024 年发布的心衰领域 10 篇具有重大影响的研究。

A novel transcatheter-implanted system that shunts blood flow from the left to right atrium through the coronary sinus has ...

Bayer has filed its mineralocorticoid receptor antagonist (MRA) finerenone as a treatment for a common form of heart failure ...

Slower gait speed, but not handgrip strength or muscle mass, is associated with an increased risk for cardiovascular outcomes ...

Berlin: Bayer has announced the submission of a marketing authorization application to the European Medicines Agency (EMA), ...

These early data are reassuring, but there are many questions yet to be explored in the upcoming pivotal trial, Nancy ...

There is an unmet need for therapies targeting Duchenne muscular dystrophy (DMD)–related heart disease, and phase 2 results ...

Finerenone is the first drug targeting the mineralocorticoid receptor (MR) pathway to demonstrate cardiovascular benefits in a Phase III study in patients ...

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) released topline results from its Phase 2 FIGHT DMD trial. The study evaluated ...